Skip to main content
SpringerLink
Log in

Topoisomerase I involvement in schedule-dependent interaction between 5-fluoro-uracil and irinotecan in the treatment of colorectal cancer

  • Letter to the Editor
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

5-Fluoro-uracil (5FU), an antimetabolite drug, stimulates expression of topoisomerase I (tpI) in adenocarcinoma cancer cells. When 5FU is given in combination with Irinotecan (IR), a tpI poison, the most effective regimen is represented by IR given before low doses of 5FU. Hence, despite their distinct mechanisms of action, the molecular basis for successful combination and schedule of 5FU and IR in the treatment of colorectal cancer rests on the opposing drug effects on the expression and poisoning of the tpI enzyme.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Tsavaris N, Lazaris A, Kosmas C et al (2008) Topoisomerase I and II alpha protein expression in primary colorectal cancer and recurrences following 5-fluorouracil-based adjuvant chemotherapy. Cancer Chemother Pharmacol. doi:10.1007/s00280-008-0886-4

  2. Richter SN, Cartei G, Nadai M et al (2006) In vitro basis for schedule-dependent interaction between gemcitabine and topoisomerase-targeted drugs in the treatment of colorectal cancer. Ann Oncol 17(Suppl 5):v20–v24

    Article  PubMed  Google Scholar 

  3. Berenbaum MC (1989) What is synergy? Pharmacol Rev 41:93–141

    PubMed  CAS  Google Scholar 

  4. National Cancer Institute (2008) Stage IV and recurrent colon cancer in Physician Data Query (PDQ®): colon cancer treatment. Available at http://www.cancer.gov/cancertopics/pdq/treatment/colon/HealthProfessional/page10. Accessed 18 December 2008

  5. Mao Y, Muller MT (2003) Down modulation of topoisomerase I affects DNA repair efficiency. DNA Repair (Amst) 2:1115–1126

    Article  CAS  Google Scholar 

  6. Mielke C, Kalfalah FM, Christensen MO, Boege F (2007) Rapid and prolonged stalling of human DNA topoisomerase I in UVA-irradiated genomic areas. DNA Repair (Amst) 6:1757–1763

    Article  CAS  Google Scholar 

Download references

Conflict of interest statement

None.

Author information

Authors and Affiliations

  1. Department of Histology, Microbiology and Medical Biotechnologies, University of Padua, Padua, Italy

    Sara N. Richter, Matteo Nadai & Giorgio Palù

  2. Department of Pharmaceutical Sciences, University of Padua, Padua, Italy

    Manlio Palumbo

Authors
  1. Sara N. Richter
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Matteo Nadai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Manlio Palumbo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Giorgio Palù
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sara N. Richter.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Richter, S.N., Nadai, M., Palumbo, M. et al. Topoisomerase I involvement in schedule-dependent interaction between 5-fluoro-uracil and irinotecan in the treatment of colorectal cancer. Cancer Chemother Pharmacol 64, 199–200 (2009). https://doi.org/10.1007/s00280-009-0971-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-009-0971-3

Keywords

Search

Navigation